CUSA® with Tissue Select®, allows you to overcome significant surgical challenges, enabling you to increase safety and precision around critical structures during tumour resection. This ultimately leads to efficiency, maximum tumour resection and fewer complications.
For Low grade glioma (grade II) resections, evidence suggests that leaving even 10cm3 of tumour behind gives the patient a reduced life prognosis*.
The same study shows that:
15% to 25% of patients with residual tumours have died within 6 years of the surgery vs none of the patients with no residual tumour left*.
For 90% of the patients where more than 50% of the tumour was left behind, the research shows that their life expectancy decreased by 2 years when compared to patients whose tumour resection was between 50% and 99%*.
*Spontaneous and therapeutic prognosis factors in adult hemispheric WHO Grade II gliomas: a series of 1097 cases, L. Capelle et al.
Key data(i) :
the power of a leading technology
The Tissue Select® difference
CUSA® Clarity system can provide you with the versatility needed in your surgical procedures to be able to adapt Power and Selectivity.
Learn more